Table 4.
Percentage of patients receiving neoadjuvant chemotherapy by stage 2010–2012.
| Overall N (%) |
Academic N (%) |
Comprehensive Community N (%) |
Community N (%) |
P value | |
|---|---|---|---|---|---|
| Borderline lumpectomy-eligible patients | |||||
| Stage IIA (T2N0 only) | |||||
| HR+/HER2− | 2,078 (11) | 714 (12) | 1,215 (11) | 149 (8) | <.001 |
| HR+/HER2+ | 891 (25) | 304 (27) | 530 (26) | 57 (16) | <.001 |
| HR−/HER2+ | 484 (30) | 166 (33) | 275 (30) | 43 (25) | .12 |
| Triple negative | 1,822 (30) | 700 (35) | 983 (29) | 139 (22) | <.001 |
| Stage IIB | |||||
| HR+/HER2− | 3,180 (37) | 1,195 (39) | 1,744 (37) | 241 (30) | <.001 |
| HR+/HER2+ | 1,308 (55) | 477 (58) | 737 (54) | 94 (44) | <.001 |
| HR−/HER2+ | 749 (59) | 288 (64) | 402 (58) | 59 (50) | .006 |
| Triple negative | 1,894 (60) | 783 (66) | 966 (57) | 145 (47) | <.001 |
| Stage IIIA (T3N1 only) | |||||
| HR+/HER2− | 1,421 (68) | 599 (72) | 722 (66) | 100 (65) | .01 |
| HR+/HER2+ | 530 (81) | 233 (83) | 254 (81) | 43 (77) | .52 |
| HR−/HER2+ | 348 (83) | 150 (89) | 168 (79) | 30 (81) | .02 |
| Triple negative | 704 (84) | 294 (89) | 355 (81) | 55 (71) | <.001 |
| Locally-advanced patients | |||||
| Stage IIIA (T0-3N2 only) | |||||
| HR+/HER2− | 801 (43) | 303 (48) | 434 (43) | 64 (28) | <.001 |
| HR+/HER2+ | 250 (46) | 94 (49) | 130 (46) | 26 (41) | .50 |
| HR−/HER2+ | 176 (58) | 55 (66) | 99 (57) | 22 (48) | .11 |
| Triple negative | 473 (63) | 175 (68) | 250 (63) | 48 (55) | .07 |
| Stage IIIB non-inflammatory | |||||
| HR+/HER2− | 877 (76) | 330 (78) | 455 (76) | 92 (67) | .02 |
| HR+/HER2+ | 272 (85) | 86 (88) | 155 (83) | 31 (84) | .61 |
| HR−/HER2+ | 241 (90) | 87 (91) | 126 (90) | 28 (88) | .88 |
| Triple negative | 371 (83) | 151 (89) | 183 (82) | 37 (66) | <.001 |
| Stage IIIC non-inflammatory | |||||
| HR+/HER2− | 430 (48) | 160 (57) | 237 (45) | 33 (35) | <.001 |
| HR+/HER2+ | 182 (58) | 63 (64) | 101 (58) | 18 (43) | .06 |
| HR−/HER2+ | 157 (67) | 64 (74) | 77 (64) | 16 (62) | .21 |
| Triple negative | 352 (74) | 138 (79) | 192 (74) | 22 (52) | .002 |
| Inflammatory (T4d) | |||||
| HR+/HER2− | 504 (93) | 176 (95) | 277 (94) | 51 (88) | .20 |
| HR+/HER2+ | 273 (94) | 99 (93) | 141 (94) | 33 (94) | .97 |
| HR−/HER2+ | 259 (94) | 87 (95) | 143 (95) | 29 (85) | .12 |
| Triple negative | 378 (96) | 133 (96) | 206 (97) | 39 (95) | .88 |
Abbreviations: HR, Hormone Receptor. HER2, Human Epidermal Growth Factor Receptor 2.